Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation

Norman Saffra, Benjamin Reinherz

Research output: Contribution to journalArticlepeer-review

Abstract

A 47-year-old woman with a medical history of pseudoxanthoma elasticum and associated choroidal neovascularisation that was successfully managed with intravitreal bevacizumab injections developed non-squamous non-small cell lung carcinoma. The patient's oncological medication regimen included systemic bevacizumab. During the 22 months that the patient received systemic bevacizumab for management of her malignancy, intravitreal bevacizumab injections were held and the patient's visual acuity remained stable and the subretinal space was free of fluid leakage.

Original languageEnglish
JournalBMJ Case Reports
DOIs
StatePublished - 13 May 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Systemic bevacizumab for simultaneous treatment of cancer and choroidal neovascularisation'. Together they form a unique fingerprint.

Cite this